References
- Pinto P, Shelar T, Nawadkar V, et al. The epidemiology of FVIII Inhibitors in Indian haemophilia A patients. Indian J Hematol Blood Transfus 2014; 30(4): 356-63. doi: 10.1007/s12288-014-0342-z.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1-158. doi: 10.1111/hae.14046.
- Pratt KP, Arruda VR, Lacroix-Desmazes S. Inhibitors – Recent insights. Haemophilia 2021; 27 Suppl 3: 28-36. doi: 10.1111/hae.14077.
- Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374(21): 2054-64. doi: 10.1056/NEJMoa1516437.
- Sachdeva A, Gunasekaran V, Ramya HN, et al. Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia. Indian Pediatr 2018; 55(7): 582-90. doi: 10.1007/s13312-018-1302-8.
- Phadke S. Hemophilia care in India: a review and experience from a tertiary care centre in Uttar Pradesh. Indian J Hematol Blood Transfus 2011; 27(3): 121-6. doi: 10.1007/s12288-011-0084-0.
- Rangarajan S, Austin S, Goddard NJ, et al. Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia 2013; 19(2): 294-303. doi: 10.1111/hae.12028.
- Ghosh K, Shetty S, Kulkarni B, et al. Development of inhibitors in patients with haemophilia from India. Haemophilia 2001; 7(3): 273-8. doi: 10.1046/j.1365-2516.2001.00505.x.
- Kumar S, Sinha S, Bharti A, Meena LP, Gupta V, Shukla J. A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India. J Family Med Prim Care 2019; 8(7): 2463-7. doi: 10.4103/jfmpc.jfmpc_316_19.
- Shah S, Patel T, Bhatnagar N, Gajjar M, Shah M, Tripathi S. “Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A study of 276 patients in Western India. Global Journal of Transfusion Medicine 2019; 4(2): 168. doi: 10.4103/GJTM.GJTM_35_19.
- Lichtman M, Kaushansky K, Prchal J, Levi M, Burns L, Linch DC. Williams Manual of Hematology, 10th edn. 2022. Columbus, OH: McGraw-Hill Education.
- Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2010; 16(102): 20-4. doi: 10.1111/j.1365-2516.2008.01924.x.
- Jadhav U, Mukherjee K, Lalwani A. Ethical issues in the care of persons living with haemophilia in India. Indian J Med Ethics 2014; 11(4): 223-7. doi: 10.20529/IJME.2014.056.
- Per capita national income across India from financial year 2015 to 2018, with estimates until 2023. Statista. 23 August 2023. Available from: https://www.statista.com/statistics/802122/india-net-national-income-per-capita/ (accessed 14 September 2023).
- Malkan UY, Aksu S. Combination of NovoSeven and FEIBA in hemophiliac patients with inhibitors. Open Med (Wars) 2018; 13: 618-21. doi: 10.1515/med-2018-0090.
- Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: The ups and downs of treatment. Blood Rev 2021; 50: 100852. doi: 10.1016/j. blre.2021.100852.
- Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med 2018; 379(9): 811-22. doi: 10.1056/NEJMoa1803550.
- Linari S, Castaman G. Concomitant use of rFVIIa and emicizumab in people with hemophilia A with inhibitors: current perspectives and emerging clinical evidence. Ther Clin Risk Manag 2020; 16: 461-9. doi: 10.2147/TCRM.S205310.
- Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10 Suppl 2: 3-9. doi: 10.1111/j.1365-2516.2004.00934.x.
- Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018; 24(3): 344-7. doi: 10.1111/hae.13495.
- Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10(4): 397-400. doi: 10.1111/j.1365-2516.2004.00924.x.
- Kizilocak H, Marquez-Casas E, Malvar J, Young G. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia 2023; 29(1): 100-5. doi: 10.1111/hae.14684.
- Radhakrishnan N, Shankar R, Maji M, Rana M. Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India. Pediatric Hematology Oncology Journal 2021; 6(2):97-9. doi: 10.1016/j. phoj.2021.03.004.